<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Thu, 03 Sep 2026 17:41:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Form  4          BIO-RAD LABORATORIES,     For: Sep 01  Filed by: BARRY JAMES</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+BARRY+JAMES/27026191.html</link>
   <description>si-local-file:///var/storage/secattach/20260903/27026191.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+BARRY+JAMES/27026191.html</guid>
   <pubDate>Thu, 03 Sep 2026 17:41:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Form  4          BIO-RAD LABORATORIES,     For: Sep 01  Filed by: BARRY JAMES</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+BARRY+JAMES/27026191.html</link>
   <description>si-local-file:///var/storage/secattach/20260903/27026191.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+BARRY+JAMES/27026191.html</guid>
   <pubDate>Thu, 03 Sep 2026 17:41:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Form  4          BIO-RAD LABORATORIES,     For: Sep 01  Filed by: Allison Schwartz</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+Allison+Schwartz/27026182.html</link>
   <description>si-local-file:///var/storage/secattach/20260903/27026182.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+Allison+Schwartz/27026182.html</guid>
   <pubDate>Thu, 03 Sep 2026 17:39:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Form  4          BIO-RAD LABORATORIES,     For: Sep 01  Filed by: Allison Schwartz</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+Allison+Schwartz/27026182.html</link>
   <description>si-local-file:///var/storage/secattach/20260903/27026182.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+Allison+Schwartz/27026182.html</guid>
   <pubDate>Thu, 03 Sep 2026 17:39:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Form  4          BIO-RAD LABORATORIES,     For: Sep 01  Filed by: SCHWARTZ NORMAN D</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+SCHWARTZ+NORMAN+D/27026169.html</link>
   <description>si-local-file:///var/storage/secattach/20260903/27026169.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+SCHWARTZ+NORMAN+D/27026169.html</guid>
   <pubDate>Thu, 03 Sep 2026 17:36:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Form  4          BIO-RAD LABORATORIES,     For: Sep 01  Filed by: SCHWARTZ NORMAN D</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+SCHWARTZ+NORMAN+D/27026169.html</link>
   <description>si-local-file:///var/storage/secattach/20260903/27026169.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Sep+01++Filed+by%3A+SCHWARTZ+NORMAN+D/27026169.html</guid>
   <pubDate>Thu, 03 Sep 2026 17:36:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Participate+in+Fireside+Chat+During+Wells+Fargo%E2%80%99s+21st+Annual+Healthcare+Conference/27001833.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time).

&lt;/p&gt;&lt;p&gt;
A live &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FaMepMFxWv3z5SRZ9meKJzp%2F3jWGjFMjUgBB3EprgQcFJW&amp;amp;esheet=54596302&amp;amp;newsitemid=20260831154879&amp;amp;lan=en-US&amp;amp;anchor=webcast&amp;amp;index=1&amp;amp;md5=a30fe3bbfb706c9759cbfd10f8967919&quot; shape=&quot;rect&quot;&gt;webcast&lt;/a&gt; and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Finvestors.bio-rad.com%2Foverview%2Fdefault.aspx&amp;amp;esheet=54596302&amp;amp;newsitemid=20260831154879&amp;amp;lan=en-US&amp;amp;anchor=investors.bio-rad.com&amp;amp;index=2&amp;amp;md5=49dcf3b197036b716efdfe78292c6512&quot; shape=&quot;rect&quot;&gt;investors.bio-rad.com&lt;/a&gt;.

&lt;/p&gt;&lt;p&gt;
&lt;b&gt;About Bio-Rad&lt;/b&gt;

&lt;/p&gt;&lt;p&gt;
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Participate+in+Fireside+Chat+During+Wells+Fargo%E2%80%99s+21st+Annual+Healthcare+Conference/27001833.html</guid>
   <pubDate>Mon, 31 Aug 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Participate+in+Fireside+Chat+During+Wells+Fargo%E2%80%99s+21st+Annual+Healthcare+Conference/27001833.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time).

&lt;/p&gt;&lt;p&gt;
A live &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FaMepMFxWv3z5SRZ9meKJzp%2F3jWGjFMjUgBB3EprgQcFJW&amp;amp;esheet=54596302&amp;amp;newsitemid=20260831154879&amp;amp;lan=en-US&amp;amp;anchor=webcast&amp;amp;index=1&amp;amp;md5=a30fe3bbfb706c9759cbfd10f8967919&quot; shape=&quot;rect&quot;&gt;webcast&lt;/a&gt; and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Finvestors.bio-rad.com%2Foverview%2Fdefault.aspx&amp;amp;esheet=54596302&amp;amp;newsitemid=20260831154879&amp;amp;lan=en-US&amp;amp;anchor=investors.bio-rad.com&amp;amp;index=2&amp;amp;md5=49dcf3b197036b716efdfe78292c6512&quot; shape=&quot;rect&quot;&gt;investors.bio-rad.com&lt;/a&gt;.

&lt;/p&gt;&lt;p&gt;
&lt;b&gt;About Bio-Rad&lt;/b&gt;

&lt;/p&gt;&lt;p&gt;
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Participate+in+Fireside+Chat+During+Wells+Fargo%E2%80%99s+21st+Annual+Healthcare+Conference/27001833.html</guid>
   <pubDate>Mon, 31 Aug 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference</title>
   <link>http://www.streetinsider.com/Business+Wire/Bio-Rad+to+Participate+in+Fireside+Chat+During+Wells+Fargo%E2%80%99s+21st+Annual+Healthcare+Conference/27001833.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time).

&lt;/p&gt;&lt;p&gt;
A live &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FaMepMFxWv3z5SRZ9meKJzp%2F3jWGjFMjUgBB3EprgQcFJW&amp;amp;esheet=54596302&amp;amp;newsitemid=20260831154879&amp;amp;lan=en-US&amp;amp;anchor=webcast&amp;amp;index=1&amp;amp;md5=a30fe3bbfb706c9759cbfd10f8967919&quot; shape=&quot;rect&quot;&gt;webcast&lt;/a&gt; and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Finvestors.bio-rad.com%2Foverview%2Fdefault.aspx&amp;amp;esheet=54596302&amp;amp;newsitemid=20260831154879&amp;amp;lan=en-US&amp;amp;anchor=investors.bio-rad.com&amp;amp;index=2&amp;amp;md5=49dcf3b197036b716efdfe78292c6512&quot; shape=&quot;rect&quot;&gt;investors.bio-rad.com&lt;/a&gt;.

&lt;/p&gt;&lt;p&gt;
&lt;b&gt;About Bio-Rad&lt;/b&gt;

&lt;/p&gt;&lt;p&gt;
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Bio-Rad+to+Participate+in+Fireside+Chat+During+Wells+Fargo%E2%80%99s+21st+Annual+Healthcare+Conference/27001833.html</guid>
   <pubDate>Mon, 31 Aug 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference</title>
   <link>http://www.streetinsider.com/Business+Wire/Bio-Rad+to+Participate+in+Fireside+Chat+During+Wells+Fargo%E2%80%99s+21st+Annual+Healthcare+Conference/27001833.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time).

&lt;/p&gt;&lt;p&gt;
A live &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FaMepMFxWv3z5SRZ9meKJzp%2F3jWGjFMjUgBB3EprgQcFJW&amp;amp;esheet=54596302&amp;amp;newsitemid=20260831154879&amp;amp;lan=en-US&amp;amp;anchor=webcast&amp;amp;index=1&amp;amp;md5=a30fe3bbfb706c9759cbfd10f8967919&quot; shape=&quot;rect&quot;&gt;webcast&lt;/a&gt; and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Finvestors.bio-rad.com%2Foverview%2Fdefault.aspx&amp;amp;esheet=54596302&amp;amp;newsitemid=20260831154879&amp;amp;lan=en-US&amp;amp;anchor=investors.bio-rad.com&amp;amp;index=2&amp;amp;md5=49dcf3b197036b716efdfe78292c6512&quot; shape=&quot;rect&quot;&gt;investors.bio-rad.com&lt;/a&gt;.

&lt;/p&gt;&lt;p&gt;
&lt;b&gt;About Bio-Rad&lt;/b&gt;

&lt;/p&gt;&lt;p&gt;
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Bio-Rad+to+Participate+in+Fireside+Chat+During+Wells+Fargo%E2%80%99s+21st+Annual+Healthcare+Conference/27001833.html</guid>
   <pubDate>Mon, 31 Aug 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	  </item>
  <item>
   <title>Form  10-Q       BIO-RAD LABORATORIES,     For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jun+30/26866787.html</link>
   <description>si-local-file:///var/storage/secattach/20260804/26866787.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jun+30/26866787.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:21:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	  </item>
  <item>
   <title>Form  10-Q       BIO-RAD LABORATORIES,     For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jun+30/26866787.html</link>
   <description>si-local-file:///var/storage/secattach/20260804/26866787.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jun+30/26866787.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:21:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	  </item>
  <item>
   <title>Form  10-Q       BIO-RAD LABORATORIES,     For: Jun 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jun+30/26866787.html</link>
   <description>si-local-file:///var/storage/secattach/20260804/26866787.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jun+30/26866787.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:21:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	  </item>
  <item>
   <title>Form  8-K        BIO-RAD LABORATORIES,     For: Jul 31</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jul+31/26866650.html</link>
   <description>si-local-file:///var/storage/secattach/20260804/26866650.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jul+31/26866650.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:16:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	  </item>
  <item>
   <title>Form  8-K        BIO-RAD LABORATORIES,     For: Jul 31</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jul+31/26866650.html</link>
   <description>si-local-file:///var/storage/secattach/20260804/26866650.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jul+31/26866650.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:16:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	  </item>
  <item>
   <title>Form  8-K        BIO-RAD LABORATORIES,     For: Jul 31</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jul+31/26866650.html</link>
   <description>si-local-file:///var/storage/secattach/20260804/26866650.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Jul+31/26866650.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:16:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
  <item>
   <title>Bio-Rad Reports Second-Quarter 2026 Financial Results</title>
   <link>http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</link>
   <description>
&lt;p&gt;    HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.

&lt;/p&gt;&lt;p&gt;
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Second-Quarter+2026+Financial+Results/26866575.html</guid>
   <pubDate>Tue, 04 Aug 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.29655321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50210587</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">BIO.B</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00005917</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14972255</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.23727637</category>
   	  </item>
 </channel>
</rss>
